2-(4-甲氧基苯氧基)乙酰胺 | 30893-64-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(4-甲氧基苯氧基)乙酰胺
• 英文名称: 2-(4-methoxyphenoxy)acetamide
• 英文别名: (4-methoxy-phenoxy)-acetic acid amide；(4-Methoxy-phenoxy)-essigsaeure-amid；4-Methoxy-phenoxyacetamid
• CAS: 30893-64-2
• 化学式: C₉H₁₁NO₃
• mdl: MFCD00234553
• 分子量: 181.191
• InChiKey: KUPMGNARMIATFA-UHFFFAOYSA-N

物化性质

• 熔点：
  116 °C
• 沸点：
  384.8±22.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)
• 溶解度：
  >27.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090
• 储存条件：
  室温

SDS

Name:	2-(4-Methoxyphenoxy)acetamide 97% Material Safety Data Sheet
Synonym:
CAS:	30893-64-2

Section 1 - Chemical Product MSDS Name:2-(4-Methoxyphenoxy)acetamide 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
30893-64-2	2-(4-Methoxyphenoxy)acetamide	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 30893-64-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 114 - 116 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H11NO3
Molecular Weight: 181

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 30893-64-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-(4-Methoxyphenoxy)acetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 30893-64-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 30893-64-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 30893-64-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(4-甲氧基苯氧基)乙酰胺 在 二乙二醇二甲醚 、 diborane(6) 作用下， 生成 2-(4-甲氧基苯氧基)乙胺
  参考文献：
  名称：

  Discovery of a new series of 5-HT1A receptor agonists

  摘要：

  Starting from compounds previously identified as alpha(1)-adrenoceptor antagonists that were also found to bind to the 5-HT1A receptor, in an attempt to separate the two activities, a new series of 5-HT1A receptor agonists was identified and shown to have high potency and/or high selectivity. Of these, compound 13, which combines high selectivity (5-HT1A/alpha(1) = 151) and good agonist potency (pD(2) = 7.82; E-max = 76), was found to be the most interesting. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.030
• 作为产物：
  描述：

  对甲氧基苯氧乙酸 在 silica gel 、 氯化铵 、 三乙胺 、 对甲苯磺酰氯 作用下， 反应 0.02h， 以90%的产率得到2-(4-甲氧基苯氧基)乙酰胺
  参考文献：
  名称：

  Efficient method for the direct preparation of amides from carboxylic acids using tosyl chloride under solvent-free conditions

  摘要：

  A simple, clean and highly efficient solvent-free procedure for the preparation of primary, secondary, tertiary and aromatic amides is described from the direct reaction of carboxylic acids and silica-supported ammonium salts, triethylamine (TEA) and tosyl chloride (TsCI) as condensing agent. The reaction proceeds rapidly in high yields at room temperature. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.08.021

文献信息

• Synthesis and Biological Evaluation of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors
  作者：Wei Shen、Shian Yu、Jiaming Zhang、Weizheng Jia、Qing Zhu

  DOI：10.3390/molecules191118620

  日期：——

  Monoamine oxidases (EC 1.4.3.4; MAOs), a family of FAD-containing enzymes, is an important target for antidepressant drugs. In this paper, a series of 2-phenoxyacetamide analogues were synthesized, and their inhibitory potency towards monoamine oxidases A (MAO-A) and B (MAO-B) were evaluated using enzyme and cancer cell lysate. 2-(4-Methoxyphenoxy)acetamide (compound 12) (SI = 245) and (2-(4-((prop-2-ynylimino)methyl)phenoxy)acetamide (compound 21) (IC50MAO-A = 0.018 μM, IC50MAO-B = 0.07 μM) were successfully identified as the most specific MAO-A inhibitor, and the most potent MAO-A/-B inhibitor, respectively. The inhibitory activities of these two compounds in living cells were also further evaluated utilizing HepG2 and SHSY-5Y cell lysates.

  单胺氧化酶（EC 1.4.3.4；MAOs）是一类含有FAD的酶，是抗抑郁药物的重要靶点。本文中，合成了一系列2-苯氧乙酰胺类似物，并使用酶和癌细胞裂解液评估了它们对单胺氧化酶A（MAO-A）和B（MAO-B）的抑制活性。成功鉴定出2-（4-甲氧基苯氧基）乙酰胺（化合物12）（SI = 245）和2-（4-（（丙-2-炔基亚氨基）甲基）苯氧基）乙酰胺（化合物21）（IC50MAO-A = 0.018 μM，IC50MAO-B = 0.07 μM）分别作为最特异的MAO-A抑制剂和最强的MAO-A/-B抑制剂。还利用HepG2和SHSY-5Y细胞裂解液进一步评估了这两种化合物在活细胞中的抑制活性。
• 1,3-Disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their Use in Medicaments
  申请人：Oberboersch Stefan

  公开号：US20090137573A1

  公开（公告）日：2009-05-28

  1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides corresponding to formula I methods for their production, pharmaceutical compositions containing them, and the use thereof for noradrenalin receptor regulation, particularly for inhibiting noradrenalin reuptake, and/or for 5-HT receptor regulation, particularly for inhibiting 5-hydroxy tryptophan reuptake, and/or for opioid receptor regulation and/or for batrachotoxin (BTX) receptor regulation and/or for treating or inhibiting pain and other conditions.

  1,3-二取代的4-甲基-1H-吡咯-2-甲酰胺对应于公式I，其制备方法，含有它们的药物组合物，以及用于去甲肾上腺素受体调节的用途，特别是用于抑制去甲肾上腺素再摄取，和/或用于5-HT受体调节，特别是用于抑制5-羟色氨酸再摄取，和/或用于阿片受体调节和/或用于蟾毒素（BTX）受体调节和/或用于治疗或抑制疼痛和其他病况。
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2005051895A1

  公开（公告）日：2005-06-09

  Disclosed are δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

  揭示了具有抑制肾素作用的δ-氨基-Ϝ-羟基-ω-芳基-烷酸酰胺化合物的化学式(I)及其盐。还揭示了包含这些化合物的药物组合物以及用于治疗高血压、动脉粥样硬化、不稳定性冠状动脉综合征、充血性心力衰竭、心肌肥大、心脏纤维化、心肌病后梗死、不稳定性冠状动脉综合征、舒张功能障碍、慢性肾脏疾病、肝纤维化、糖尿病引起的并发症（如肾病、血管病和神经病变）、冠状动脉疾病、血管成形术后再狭窄、眼内压升高、青光眼、异常血管生长、高醛固酮症、认知障碍、阿尔茨海默病、痴呆、焦虑状态和认知障碍的治疗方法。
• [EN] BICYCLIC COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSES BICYCLIQUES ET LEUR UTILISATION THERAPEUTIQUE
  申请人：ARGENTA DISCOVERY LTD

  公开号：WO2005035526A1

  公开（公告）日：2005-04-21

  Compounds of the formula (1) are useful as MCH mediator, and in the therapy of obesity.

  化合物的公式（1）在MCH介质和肥胖症治疗中有用。
• Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
  申请人：Bradley Edward Stuart

  公开号：US20050261272A1

  公开（公告）日：2005-11-24

  Compounds represented by Formula (I): or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants.

  化学式（I）所代表的化合物或其药学上可接受的盐，是糖原磷酸化酶的抑制剂，可用于预防或治疗糖尿病、高血糖、高胆固醇血症、高胰岛素血症、高血脂症、高血压、动脉粥样硬化或组织缺血，例如心肌缺血，并作为心脏保护剂。